NEW YORK (TheStreet) -- Shares ofNeuroDerm (NDRM) skyrocketed more than 65% to a 52-week high of $10.31 in morning trading Tuesday after the Israeli company announced encouraging results from a trial for a treatment of Parkinson's disease. NeuroDerm announcedcontinuous, subcutaneous dosage of two of its proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, resulted in clinically significant plasma levadopa levels. The data indicates thatthe high dose version, ND0612H, meant for patients with severe Parkinson's disease, could be an effective therapy alternative to current treatments that require surgery. "Maintaining consistent levodopa concentrations has been the most significant hurdle in Parkinson's disease therapy," said Sheila Oren, MD, NeuroDerm's Vice President of Clinical and Regulatory Affairs. Exclusive Report: Jim Cramers Best Stocks for 2015 Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade. Access the tool that DOMINATES the Russell 2000 and the S&P 500. Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar. View post: NeuroDerm (NDRM) Stock Skyrockets to One-Year High After Encouraging Parkinson's Treatment Results … Continue reading →

Clinical-stage pharmaceutical company NeuroDerm Ltd. (NDRM: Quote), which went public in November, announced Tuesday topline results for a mid-stage study for its proprietary liquid levodopa/carbidopa (LD/CD) product candidates as a treatment for Parkinson's disease. Following the announcement, the company's shares are skyrocketing more than 49 percent in early deals. The company said the continuous, subcutaneous delivery of the liquid product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. The company added that ND0612H, the higher dose version, provided an effective alternative to current treatments that require surgery. "Maintaining consistent levodopa concentrations has been the most significant hurdle in Parkinson's disease therapy. The results from this study demonstrate that ND0612H can reach high LD plasma levels that, to date, could only be reached and maintained by products that require surgical intervention," said Sheila Oren, NeuroDerm's Vice President of Clinical and Regulatory Affairs. The phase IIa study was conducted on 16 patients with an advanced form of Parkinson's disease having motor fluctuations that was chronically treated with standard of care oral LD/CD. The primary endpoints of the study were to assess the safety, tolerability and pharmacokinetics (PK) of six dose regimens of ND0612H and ND0612L. The patients were treated with … Continue reading →

Rehovot-based Central Nervous Systems treatment drug developer NeuroDerm(Nasdaq:NDRM) has achieved positive results in a Phase IIa Pharmacokinetic Study of ND0612H and ND0612L for the treatment of Parkinsons disease. These results suggest that the high dose version, ND0612H, intended for severe Parkinsons disease patients, may provide an effective therapy alternative to current treatments requiring surgery. Following publication of the results the company's share price rose 194% to $18.14, giving a market cap of $308 million, well above Neuroderm's share price of $10 at its IPO last month, when it raised $50 million. NeuroDerm VP Clinical and Regulatory Affairs Dr. Sheila Oren said, Maintaining consistent levodopa concentrations has been the most significant hurdle in Parkinsons disease therapy. The results from this study demonstrate that ND0612H can reach high LD plasma levels that, to date, could only be reached and maintained by products that require surgical intervention. ND0612H is designed to be delivered continuously, thus we believe it should offer a simple and effective treatment option that will minimize the need for surgical intervention in advanced Parkinsons patients. NeuroDerm CEO Dr. Oded Lieberman said, These results add to the growing body of clinical data confirming our thesis that continuous, subcutaneous delivery of LD/CD … Continue reading →

Aquinox Pharmaceuticals Inc. (AQXP: Quote) has initiated dosing in a phase II clinical trial of AQX-1125 for the treatment of atopic dermatitis. The trial, dubbed KINSHIP, designed to enroll about 50 adult patients with mild to moderate atopic dermatitis is being conducted at clinical research centers in Canada. AQXP closed Tuesday's trading 6.46% higher at $7.25. ARIAD Pharmaceuticals Inc. (ARIA: Quote) has granted Angelini Pharma exclusive rights to commercialize leukemia drug Iclusig in seven Central and Eastern European countries. The seven countries include Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia. The commercial launches of Iclusig in these Central and Eastern European countries are expected to begin in 2015. With this distributorship in place, Iclusig will be available to patients with resistant and intolerant Philadelphia-positive leukemias in more than 23 countries in Europe. Net product revenues from sales of Iclusig were $14.5 million for the quarter ended September 30, 2014, an increase of 22% from the second quarter of 2014. ARIA closed Tuesday's trading at $6.82, down 1.23%. In after-hours, the stock was up 1.25% at $6.90. Idera Pharmaceuticals Inc.'s (IDRA: Quote) drug candidate IMO-8400 has been granted orphan drug designation by FDA for the treatment of Waldenstrm's … Continue reading →